Sutro Biopharma Appoints Greg Chow as CFO to Advance ADC Pipeline
Key Insights
Sutro Biopharma appointed Greg Chow (search) as Chief Financial Officer effective June 2, 2025, bringing over 25 years of executive leadership experience in biotech finance and operations.
Chow previously served as CFO at multiple biotech companies including Freenome Holdings (search) and Frontier Medicines (search), where he guided major financing rounds and strategic collaborations.
The appointment aims to strengthen Sutro's financial position as the company advances its pipeline of novel exatecan-based and dual-payload antibody drug conjugates (search) through clinical milestones.
Sutro Biopharma, an oncology company pioneering site-specific and novel-format antibody drug conjugates (search) (ADCs), announced the appointment of Greg Chow (search) as Chief Financial Officer effective June 2, 2025. The appointment comes as the South San Francisco-based company advances its pipeline of precisely designed cancer (search) therapeutics through clinical development.
Executive Leadership Addition
Chow brings over 25 years of executive leadership experience across corporate finance, capital markets, investment banking, financial accounting, and drug development operations. "Greg brings a strong track record of driving financial discipline, operational efficiency, and capital strategy across both private and public biotech companies," said Jane Chung (search), Chief Executive Officer of Sutro. "His leadership will be instrumental in ensuring we are well-positioned financially to achieve key clinical milestones across our wholly-owned pipeline of novel exatecan-based and dual-payload ADCs."
The new CFO expressed enthusiasm about joining the company at this stage of development. "It's an incredibly exciting time to join Sutro. The Company is uniquely positioned at the forefront of ADC innovation, with a robust pipeline, high value collaborations, and a powerful cell-free technology platform that enables precise, efficient drug discovery," Chow stated.
Extensive Biotech Finance Background
Chow's recent experience includes serving as Chief Financial and Business Officer at NodThera (search), where he played a key role in business development and financing activities. Prior to that role, he served as CFO at Freenome Holdings (search), where he helped successfully execute the Series F round, and CFO at Frontier Medicines (search), guiding the Series B and C financings while overseeing Alliance Management for a major global collaboration with AbbVie (search).
His experience extends to public company leadership, having served as Executive Vice President and CFO at Aptose Biosciences (search), where he oversaw the company's dual listing on Nasdaq and the Toronto Stock Exchange and raised more than $225 million in capital. Earlier in his career, Chow spent 14 years in investment banking, holding senior roles at Wedbush Securities, RBC Capital Markets, and Wells Fargo Securities.
Educational and Professional Credentials
Chow holds an MBA in Finance from the Wharton School at the University of Pennsylvania and a BA in Business Economics from the University of California, Santa Barbara. He is also a Certified Public Accountant (inactive) in the state of California.
Equity Compensation Package
The Compensation Committee of Sutro's Board of Directors granted Chow a restricted stock unit award for 100,000 shares and a non-qualified option to purchase 275,000 shares of Sutro's common stock under the company's 2021 Equity Inducement Plan. The option will have an exercise price equal to the closing price of Sutro's common stock on June 2, 2025. The restricted stock award vests at 25% of the shares annually, while the option award vests at 25% of the shares on the one-year anniversary of its grant, with the remainder vesting ratably over 36 months thereafter.
Company Technology Platform
Sutro focuses on the discovery and development of precisely designed cancer (search) therapeutics using its fit-for-purpose technology, including cell-free XpressCF®. The company is advancing a robust early-stage pipeline of novel exatecan and dual-payload antibody drug conjugates (search), coupled with high-value collaborations and industry partnerships that validate its continuous product innovation.